ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024
Автор: Cancer Research and Statistic Foundation
Загружено: 2025-07-01
Просмотров: 38
Описание:
This video highlights new molecular residual disease (MRD) findings from the ADAURA trial, presented at ASCO 2024. The study evaluates MRD as a predictive biomarker in patients with resected EGFR-mutated stage IB–IIIA non-small cell lung cancer (NSCLC) receiving adjuvant osimertinib.
📌 Learn how MRD is shaping the future of precision oncology in lung cancer.
#ADAURATrial #MRD #EGFRNSCLC #Osimertinib #ASCO2024 #LungCancer #TargetedTherapy #NSCLC
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке: